Myriad Genetics, Inc. (MYGN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Veracyte, Inc.

AtriCure, Inc.

STAAR Surgical Co.

Tandem Diabetes Care, Inc.

TransMedics Group, Inc.

Pacific Biosciences of California, Inc.

PROCEPT BioRobotics Corp.

NovoCure Ltd.

Alphatec Holdings, Inc.

Myriad Genetics, Inc.

Owens & Minor, Inc.

Why is Myriad Genetics, Inc. ?

Poor long term growth as Net Sales has grown by an annual rate of 5.24% and Operating profit at 8.01% over the last 5 years

With a fall in Net Profit of -62.72%, the company declared Very Negative results in Mar 26

INTEREST(HY) At USD 8.5 MM has Grown at 466.67%
PRE-TAX PROFIT(Q) At USD -28.7 MM has Fallen at -51.65%
ROCE(HY) Lowest at -76.73%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 3.37%, its profits have risen by 50.1%

Underperformed the market in the last 1 year

The stock has generated a return of 3.37% in the last 1 year, much lower than market (S&P 500) returns of 20.78%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Myriad Genetics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Myriad Genetics, Inc.

3.37%

-0.96

79.64%

S&P 500

20.78%

1.56

13.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

5.24%

EBIT Growth (5y)

8.01%

EBIT to Interest (avg)

-34.57

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.03

Sales to Capital Employed (avg)

1.22

Tax Ratio

20.09%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

0.41%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.09

EV to EBIT

-5.57

EV to EBITDA

-24.99

EV to Capital Employed

1.09

EV to Sales

0.46

PEG Ratio

Dividend Yield

ROCE (Latest)

-19.64%

ROE (Latest)

-12.64%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 2.4 MM

NET PROFIT(HY)

Higher at USD -33.9 MM

-28What is not working for the Company

INTEREST(HY)

At USD 8.5 MM has Grown at 466.67%

PRE-TAX PROFIT(Q)

At USD -28.7 MM has Fallen at -51.65%

ROCE(HY)

Lowest at -76.73%

DEBT-EQUITY RATIO (HY)

Highest at 25.82 %

RAW MATERIAL COST(Y)

Grown by 5.6% (YoY

NET PROFIT(Q)

Lowest at USD -28.7 MM

Here's what is working for Myriad Genetics, Inc.

Operating Cash Flow

Highest at USD 2.4 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Here's what is not working for Myriad Genetics, Inc.

Interest

At USD 8.5 MM has Grown at 466.67%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Pre-Tax Profit

At USD -28.7 MM has Fallen at -51.65%

over average net sales of the previous four periods of USD -18.92 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -28.7 MM has Fallen at -146.88%

over average net sales of the previous four periods of USD -11.62 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at 25.82 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Net Profit

Lowest at USD -28.7 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Raw Material Cost

Grown by 5.6% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales